Research indicates that people with this disease have a life expectancy two decades shorter than the general population. Vertex and CRISPR Therapeutics hope to provide a potentially onetime therapy in exacel which Vertex licensed in 2017 after previously partnering with the smaller biotech. Vertex says its drug development strategy revolves around picking targets where the need for new treatments